Table 4

Description of models to predict risk of mortality at several time points and their predictive ability in patients diagnosed with or without ACLF in the CANONIC (discovery set) and the PREDICT (validation set) study cohorts

ModelC-index
At 7 daysAt 14 daysAt 28 daysAt 60 daysAt 90 days
AD-ACLF patients
Discovery set: CANONIC study cohort (n=181)
 % of deaths7.73%18.23%26.52%35.91%40.33%
 CLIF-C MET 10.8680.8440.7940.7570.744
 CLIF-C MET 20.8750.8720.8190.7910.772
 CLIF-C ACLF score0.757*†0.793†0.760†0.7340.720†
 MELDNa score0.671*†‡0.711*†‡0.696*†‡0.707†0.703†
Validation set: PREDICT study cohort (n=109)
 % of deaths4.59%16.51%27.52%34.86%37.61%
 CLIF-C MET 10.9140.7240.7170.7140.714
 CLIF-C MET 20.8920.7300.7330.7220.721
 CLIF-C ACLF score0.8790.7630.7280.683†0.670*†
 MELDNa score0.601*†‡0.592*†‡0.644*†‡0.649*†0.643*†
AD-no ACLF patients
Discovery set: CANONIC study cohort (n=650)
 % of deaths0.92%2.31%4.77%9.85%12.46%
 CLIF-C MET 10.9160.8710.7810.7640.741
 CLIF-C MET 20.9420.8950.7870.7500.729
 CLIF-C AD score0.768*†0.769*†0.7520.7330.736
 MELDNa score0.715*†0.686*†‡0.693*†‡0.7230.723
Validation set: PREDICT study cohort (n=742)
 % of deaths0.67%2.83%6.06%12.40%15.36%
 CLIF-C MET 10.9280.8410.7690.7690.760
 CLIF-C MET 20.9450.8640.7810.7690.759
 CLIF-C AD score0.839*†0.798†0.7230.7150.707
 MELDNa score0.757*†‡0.726*†‡0.694*†0.668*†0.660*†‡
  • *P value <0.01 compared to the metabolomic model 1 for differences larger than 0.05.

  • †P value <0.01 compared to the metabolomic model 2 for differences larger than 0.05.

  • ‡P value <0.01 compared to the CLIF-C ACLF/CLIF-C AD score for differences larger than 0.05.

  • ACLF, acute-on-chronic liver failure; AD, acutely decompensated cirrhosis; CLIF-C ACLF, Chronic Liver Failure Consortium ACLF.